the market is not always rational. CTIC are scammers, much better are IMGN and EXEL, but the overreaction for IMGN is a pure hysteria for phase I results, whose benefit percentage normally should be reduced in a phase II-III, for a small target population of 2K-3K women, whose insurance hardly would pay the high cost of such an immunotherapy. Exel is more solid, but I am angry for the inability of SPPI team in advertising their drugs, because some are very promising.
could you , please, tell me why you are so negative on eteplirsen? I am looking at SRPT, but I don't know if it worths buying or not. Thus at the moment I have no any long-sentiment
I scrolled all the list of generics of Qualitest (the Endo generic division). I found the generic Keppra and Effexor, but not Focalin.Thus, if so, Endo does not own a generic Focalin. I suppose that the delay is motivated by the Par buyout. At the moment all Par efforts deal with the Endo agreements. Unfortunately this could last one-two more months.
did people talking of PTX debt take into account the further Zohydro rev. + the potentiality of pediatric label expansion of treximet? Or are they considering the old pipeline? Is it possible that the last disappointing QE could be episodic?
shouldthe PDUFA be scheduled on 5/14/2015? Or not??????
What do you know?
either sombody knows something or this is a short covering. I am confused because IPCI Bollinger Band and RSI are critical!!!!
I overweightd just yesterday, but now I don't know what to do, frankly speaking.
amrn is promising, even considering the chinese deal, but what do you think on orex? There are recent news on their diet drug on cv desease. please only sincere opinion.